John L. Slebir, Chief Legal Officer of ARS Pharmaceuticals, Inc., filed a Form 3 initial statement of beneficial ownership with the SEC on November 4, 2026, disclosing no securities beneficially owned as of the event date of October 26, 2026.

Key Highlights

  • Reporting person: John L. Slebir, identified as Chief Legal Officer of ARS Pharmaceuticals, Inc.
  • Event date: The date of event requiring the statement is listed as October 26, 2026.
  • Filing date: The form was filed on November 4, 2026.
  • No securities held: The filing states, "No securities are beneficially owned," with both Table I (non-derivative securities) and Table II (derivative securities) left blank.
  • Issuer: ARS Pharmaceuticals, Inc., trading on NASDAQ:SPRY.
  • Signed by: Kathleen Scott, Attorney-in-Fact, on behalf of the reporting person.

ARS Pharmaceuticals Chief Legal Officer Reports Zero Beneficial Ownership on Appointment

According to the filing, John L. Slebir submitted a Form 3 as an initial statement of beneficial ownership required under Section 16(a) of the Securities Exchange Act of 1934. The form was filed individually, as indicated by the selection of "Form filed by One Reporting Person." Slebir is listed with an address care of ARS Pharmaceuticals, Inc., at 11682 El Camino Real, Suite 300, San Diego, California 92130.

The filing discloses that Slebir holds the title of Chief Legal Officer at ARS Pharmaceuticals, Inc. (NASDAQ:SPRY). The triggering event date is recorded as October 26, 2026, which typically corresponds to the date an individual first becomes subject to Section 16 reporting obligations, such as upon appointment to a covered officer role. The form was submitted on November 4, 2026, signed by Kathleen Scott as Attorney-in-Fact.

Both Table I, covering non-derivative securities, and Table II, covering derivative securities such as options, warrants, and convertible instruments, contain no entries. The filing explicitly notes, "No securities are beneficially owned," indicating that as of the event date, Slebir held no direct or indirect beneficial ownership in any class of ARS Pharmaceuticals securities reportable under the form.

What Was Disclosed

ARS Pharmaceuticals Chief Legal Officer John L. Slebir filed an initial beneficial ownership statement reporting no securities of any type held as of October 26, 2026. The filing was submitted November 4, 2026, and signed by an Attorney-in-Fact.